Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 19/20 | 0.55 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.53 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.53 |
| ▸ | KCNH2 | Q12809 | 5/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4481722 | 0.97 | HRH3 (0.58) | HRH3CYP1A2CYP2D6KCNH2 | |
| SCHEMBL4459795 | 0.94 | CYP1A2 (0.52) | HRH3CYP1A2CYP2D6KCNH2 | |
| SCHEMBL18283452 | 0.88 | CYP1A2 (0.50) | HRH3CYP1A2CYP2D6KCNH2 | |
| SCHEMBL27179087 | 0.84 | MEN1 (0.49) | HRH3CYP1A2CYP2D6 | |
| SCHEMBL3306621 | 0.82 | HRH3 (0.47) | HRH3KCNH2 | |
| SCHEMBL8973048 | 0.81 | MAPT (0.50) | CYP1A2CYP2D6 | |
| SCHEMBL11044966 | 0.81 | EPHX2 (0.54) | — | |
| SCHEMBL16532717 | 0.81 | SIGMAR1 (0.45) | CYP1A2CYP2D6KCNH2 | |
| SCHEMBL3274096 | 0.81 | HRH3 (0.55) | HRH3KCNH2 | |
| SCHEMBL28297004 | 0.81 | SIGMAR1 (0.45) | CYP1A2CYP2D6KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 48 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-106573925-B | Process for large scale production of N- [4- (1-cyclobutylpiperidin-4-yloxy) phenyl ] -2- (morpholin-4-yl) acetamide dihydrochloride | 苏文生命科学有限公司 | 2020-04-10 | — | — | CN | claimed |
| EP-3180334-B1 | PROCESS FOR LARGE SCALE PRODUCTION OF N-[4-(1- CYCLOBUTYL PIPERIDIN-4-YLOXY) PHENYL]-2-(MORPHOLIN-4-YL) ACET AMIDE DIHYDROCHLORIDE | SUVEN LIFE SCIENCES LTD (IN) | 2018-09-26 | — | — | EP | claimed |
| US-9802896-B2 | Process for large scale production of N-[4-(1-cyclobutyl piperidin-4-yloxy) phenyl]-2-(morpholin-4-yl) acetamide dihydrochloride | SUVEN LIFE SCIENCES LIMITED (IN) | 2017-10-31 | — | — | US | claimed |
| US-20170260135-A1 | PROCESS FOR LARGE SCALE PRODUCTION OF N-[4-(1-CYCLOBUTYL PIPERIDIN-4-YLOXY) PHENYL]-2-(MORPHOLIN-4-YL) ACETAMIDE DIHYDROCHLORIDE | SUVEN LIFE SCIENCES LIMITED (IN) | 2017-09-14 | — | — | US | claimed |
| EP-3180334-A1 | PROCESS FOR LARGE SCALE PRODUCTION OF N-[4-(1- CYCLOBUTYL PIPERIDIN-4-YLOXY) PHENYL]-2-(MORPHOLIN-4-YL) ACET AMIDE DIHYDROCHLORIDE | Suven Life Sciences Limited (IN) | 2017-06-21 | — | — | EP | claimed |
| WO-2016027275-A1 | PROCESS FOR LARGE SCALE PRODUCTION OF N-[4-(1- CYCLOBUTYL PIPERIDIN-4-YLOXY) PHENYL]-2-(MORPHOLIN-4-YL) ACET AMIDE DIHYDROCHLORIDE | SUVEN LIFE SCIENCES LIMITED (IN) | 2016-02-25 | — | — | WO | claimed |
| US-20090306375-A1 | Process for production of 4(3H)-quinazolinone derivative | MSD K.K. (JP) | 2009-12-10 | — | — | US | claimed |
| EP-1900733-A1 | PROCESS FOR PRODUCTION OF 4(3H)-QUINAZOLINONE DERIVATIVE | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2008-03-19 | — | — | EP | claimed |
| US-20260048068-A1 | PHENYLUREA DERIVATIVES AND THEIR PHARMACEUTICAL USES | HANGZHOU BIO SINCERITY PHARMA TECH CO LTD (CN) | 2026-02-19 | — | — | US | disclosed |
| EP-4488263-A2 | PHENYLUREA DERIVATIVE AND PHARMACEUTICAL USE THEREOF | Hangzhou Bio-Sincerity Pharma-tech Co., Ltd. (CN) | 2025-01-08 | — | — | EP | disclosed |
| US-12172980-B2 | Compounds as neuronal histamine receptor-3 antagonists and uses thereof | XWPharma Ltd. (KY) | 2024-12-24 | — | — | US | disclosed |
| CN-116693446-A | Phenylurea derivative and medical application thereof | 杭州百诚医药科技股份有限公司 | 2023-09-05 | — | — | CN | disclosed |
| EP-3856719-B1 | COMPOUNDS AS NEURONAL HISTAMINE RECEPTOR-3 ANTAGONISTS AND USES THEREOF | XWPHARMA LTD (KY) | 2023-06-07 | — | — | EP | disclosed |
| US-20220380339-A1 | COMPOUNDS AS NEURONAL HISTAMINE RECEPTOR-3 ANTAGONISTS AND USES THEREOF | XWPharma Ltd. (KY) | 2022-12-01 | — | — | US | disclosed |
| EP-2694492-A1 | NOVEL COMPOUNDS AS HISTAMINE H3 RECEPTOR LIGANDS | Suven Life Sciences Limited (IN) | 2014-02-12 | — | — | EP | disclosed |
| CN-103443093-A | Novel compounds as histamine H3 receptor ligands | SUVEN LIFE SCIENCES LTD | 2013-12-11 | — | — | CN | disclosed |
| WO-2012114348-A1 | NOVEL COMPOUNDS AS HISTAMINE H3 RECEPTOR LIGANDS | SUVEN LIFE SCIENCES LIMITED (IN) | 2012-08-30 | — | — | WO | disclosed |
| US-20090306375-A1 | Process for production of 4(3H)-quinazolinone derivative | MSD K.K. (JP) | 2009-12-10 | — | — | US | disclosed |
| EP-1900733-A1 | PROCESS FOR PRODUCTION OF 4(3H)-QUINAZOLINONE DERIVATIVE | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2008-03-19 | — | — | EP | disclosed |
| WO-2006132424-A1 | PROCESS FOR PRODUCTION OF 4(3H)-QUINAZOLINONE DERIVATIVE | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2006-12-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220380339-A1 | COMPOUNDS AS NEURONAL HISTAMINE RECEPTOR-3 ANTAGONISTS AND USES THEREOF | HRH3, HRH4, HRH2 | HRH3 1/4885CYP1A2 1644/4885CYP2D6 1581/4885 |
| US-12172980-B2 | Compounds as neuronal histamine receptor-3 antagonists and uses thereof | HRH3, HRH4, HRH2 | HRH3 1/4885CYP1A2 2416/4885CYP2D6 2090/4885 |
| US-20260048068-A1 | PHENYLUREA DERIVATIVES AND THEIR PHARMACEUTICAL USES | HRH3, HRH2, HRH4 | HRH3 1/4885CYP1A2 1965/4885CYP2D6 70/4885 |
| US-20170260135-A1 | PROCESS FOR LARGE SCALE PRODUCTION OF N-[4-(1-CYCLOBUTYL PIPERIDIN-4-YLOXY) PHENYL]-2-(MORPHOLIN-4-YL) ACETAMIDE DIHYDROCHLORIDE | RIMKLA, QPCT, EIF4H | HRH3 3192/4885CYP1A2 72/4885CYP2D6 566/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.